Introduction
Percutaneous transluminal angioplasty (PTA) is an accepted method of treatment of critical limb ischaemia. 1~ Although PTA is also widely used in the management of intermittent claudication its true value in this situation is more controversial. 5-7 It has gained acceptance despite the known spontaneous improvement in claudication which occurs particularly with cessation of smoking and continued walking. 8 The dilemma over the optimum treatment of claudication is exemplified in the following contrasting statements: "These results justify the use of angioplasty in the treatment of intermittent claudication. "l "Conservative therapy should be primary treatment. Invasive *Presented at the 9th annual meeting of the European Society for Vascular Surgery, Antwerp, Belgium (September/October 1995). tPlease address all correspondence to: Mr M.R. Whyman, Consultant Surgeon, Department of Surgery, Cheltenham General Hospital Sandford Road, Cheltenham, Gloucestershire GL53 7AN, U.K.
procedures (angioplastN etc) should be reserved for the treatment of limb threatening events. "5 "It is debatable whether such a randomised controlled trial of PTA would now be considered ethical. " 6 The natural history of intermittent claudication has been documented in a number of large studies. 9-~5 Significant deterioration in symptoms occurs in 25-35% of patients over 3-5 years and amputation is required in 1-2% per year.9'l°Improvement in symptoms with persistent exercise is common but can take as long as a year. 16 '17 In contrast, the improvement in symptoms resulting from a technically successful angioplasty is usually immediate. Five year patency rates of 60-90% for iliac disease and 40-70% for femoral disease have been reported. 2~4 Major complications occur in 1% of claudicants) However, the only controlled trial comparing angioplasty with nonsurgical treatment (intensive walking therapy) failed to show any important benefits from angioplasty. 16 '18 The aim of this study was to compare angioplasty versus conservative treatment of intermittent claudication in a controlled clinical trial in terms of reported maximum walking distance, treadmill onset of claudication distance, treadmill maximum walking distance, ankle brachial pressure index (ABPI), arterial patency and quality of life 6 months after randomisation. Follow-up is evaluating late outcome.
Methods
Between 1991 and 1993 all patients referred to the peripheral vascular clinic at the Royal Infirmary of Edinburgh with predominantly unilateral intermittent claudication were considered for inclusion in the trial. Exclusion criteria were: previous angioplasty or arterial surgery to the symptomatic leg, myocardial infarction within the previous 6 months, patients taking oral anticoagulants, duration of symptoms less than 1 month, inability to manage the treadmill examination, and any psychiatric illness or other reason making follow-up difficult.
In the clinic a routine history and physical examination were performed. Patients were asked to estimate their maximum walking distance on the flat under normal conditions (reported maximum walking distance). A venous blood sample was taken for plasma total cholesterol estimation. After the patient had rested supine for 10 min right brachial and right and left ankle systolic pressures were measured using Doppler probe and random zero sphygmomanometer (Hawksley & Son Ltd, Lancing, Surrey, U.K.). Weight and height were measured (instrument by Seca-Delta, Germany) in light clothing without shoes. Patients completed the Nottingham Health Profile ~9 which enquires about six modalities of quality of life: pain, mobilit3~ sleep, emotion, energy and isolation. A standard treadmill test (4 km/h at 10% incline) was performed measuring the time to onset of claudication and the time to cessation of walking due to claudication, up to a maximum of 10 min. These were converted to distances: treadmill onset claudication distance, and treadmill maximum walking distance.
The symptomatic leg was examined after rest by colour Duplex using an ATL UM9 (HDI) machine (Advanced Technology Laboratories, Bothell, WA, U.S.A.). Lesions considered suitable for PTA were discrete femoral or iliac stenoses or femoropopliteal occlusions _< 10 cm long. Patients were excluded from further study if they were found to have iliac occlusion, > 10 cm length femoropopliteal occlusion, multiple stenoses or diffuse disease with long stenoses. Patients who had lesions suitable for PTA identifled on Duplex scanning then underwent percutaneous transfemoral arteriography. Those with lesions confrmed as suitable for PTA were randomised to either conventional medical treatment (low dose aspirin plus advice on smoking and exercise) or PTA by balloon dilatation plus the same medical treatment. With regard to exercise, patients were advised to continue to walk as far as possible and as frequently as possible within the limits imposed by pain. The randomisation was made by means of a telephone link to a computerised random allocation system provided by the Scottish Cancer Trials Office, University of Edinburgh. In most cases PTA was carried out in the same session as the arteriography.
Patients were followed up 3 and 6 months after randomisation. At follow up, several of the procedures carried out at baseline were repeated: treadmill exercise test, measurement of ABPI and completion of the Nottingham Health Profile questionnaire. Duplex ultrasound was also carried out to determine if the arterial site in question was patent or occluded, and if patent to assess the degree of stenosis expressed as the velocity ratio. 2° '21 Analysis was carried out using the statistical package SPSS-X. The walking distances were converted to binary variables: reported ability to walk 1 km; no symptoms after 667 m on the treadmill and the ability to reach 667 m on the treadmill. Chi-squared and Fisher's exact test were used to examine categorical differences whilst students t-test and Mann-Whitney U-test were used to examine ordinal differences between the PTA and control group at randomisation and after 6 months. Two-tailed p-values are given. The sample size was calculated as follows: A significant difference between two groups of 27 patients should be detected if significant symptomatic improvement occurred in 20% of the control group and 60% of the PTA group with a power of 90% and a type I error of 0.05. Significant improvement was arbitrarily taken as the ability to walk 667 m (10 min) on the treadmill free of pain where this was not possible before. Approval for the trial was obtained in advance from the Research Ethics Sub-Committee for Surgery. Written consent was obtained from all patients undergoing angiography.
Results
Approximately 600 claudicants were seen in the outpatients department between 1991 and 1993. Of these, 425 were initially considered suitable for trial entry and were subjected to duplex scanning. 316 patients Eur J Vasc Endovasc Surg Vol 12, August 1996 did not fulfil the inclusion criteria on the basis of Duplex findings and an additional 15 did not wish to participate in the trial at this stage. The remainder (94 patients) underwent transfemoral arteriography following which another 32 were excluded from the trial. Thus, 62 patients had disease suitable for PTA and were randomised. patients was as follows: death from myocardial infarction (1), non-attendance (2), patients inability to walk well due to recent colonic cancer surgery (1) and vein harvesting for coronary artery bypass graft (1), severe angina (1), new myocardial infarction (1), temporarily faulty treadmill machine (1) and nonspecific illness (1).
Randomisation
Randomisation allocated 30 patients to the PTA and 32 to the control group. The length of femoral occlusions in both groups was comparable: median 3cm (range 1-10) in the PTA group and median 4cm (range 2-8) in the control group. Table 1 shows the age, sex, occurrence of cardiovascular risk factors, severity of arterial disease and site and types of lesion in the two groups. No statistically significant differences were found between the two groups (p > 0.05).
Follow-up
At 6 months follow up no patient in either group had required surgery for critical ischaemia or deterioration of symptoms. No patients had opted out of the trial. Three patients in the angioplasty group also had angioplasty of the other leg within 6 months of randomisation. The reasons for incomplete data on the exercise treadmill or on Duplex scanning in some Differences in walking and ABPI between PTA and control groups at 6 months Table 2 shows the severity of arterial disease in the PTA and control groups at 6 months. The PTA group had significantly more patients with a reported walking distance of lkm (p ___ 0.05) and without claudication on treadmill exercise (p__. 0.01). The PTA group also had a significantly greater ABPI (p <_ 0.01).
Further analysis was carried out separately on femoral and iliac lesions. In the 15 patients with iliac lesions there were no demonstrable differences between PTA and control groups in the numbers reporting a walking distance of lkm, the number free of claudication on the treadmill, the number who could walk the maximum distance on the treadmill or in ABPI. However, in the 47 patients with femoral lesions the PTA group had significantly more patients who reported a walking distance of 1kin (p ___ 0.05) and who did not have claudication on treadmill exercise (p_< 0.01) in addition to having a significantly greater ABPI (p _< 0.01). The small number of patients with iliac All differences between PTA and control groups were non-significant (p>0.05). IQR, interquartile range. lesions makes interpretation of the clinical significance of these findings difficult.
Differences in lesion progression at 6 months
In the control group three new occlusions developed during follow-up. In the PTA group all seven occlusions were initially rendered patent, but one reoccluded during follow-up. Thus, there were a significantly greater number of occluded arteries in the control group than the PTA group at 6 months (p ___ 0.001). In arteries remaining patent, the degree of narrowing at the stenosis (velocity ratio) was significantly less in the PTA group (p < 0.001). In neither group was a lesion measured as longer than 10cm at 6 months so that, in principle, all were amenable to angioplasty.
Differences in quality of life at 6 months
The number of subjects responding 'yes' to one or more questions in each of the six aspects of life in the NHP is shown in Table 3 . At randomisation there were no significant differences in any of the modalities between the two groups (p > 0.05). However, at the 6 month follow up the PTA group had a lower pain score (p _< 0.05), but there were no differences between the two groups in the other quality of life modalities (p > 0.05).
Discussion
An interesting finding in this study was that 90% of the patients with intermittent claudication who were screened were, in fact, unsuitable for treatment by PTA either because of the pattern of their occlusive disease or because of other diseases. When a suitable lesion is present, however, the results of this trial have demonstrated that, in the short term, claudicants treated by PTA have less pain, improved walking and greater resting ABPI than patients managed conservatively. In particular, after PTA more patients are able to walk a set distance before the onset of pain. The only other reported randomised trial of PTA versus non-surgical treatment found intensive walking therapy to be similar to PTA in terms of maximum walking distance and daudication distance on the treadmill at a mean follow up of 69 months. 18 Furthermore, there did not appear to be a significant difference in ABPI between the two groups and the mean ABPI was lower in both groups than in this trial. A possible explanation is that patients might have had more severe disease than in this trial and indeed, our trial was exclusively concerned with patients with discrete, single segment atheromatous lesions. One reason for reporting the 6 months results of this trial Values are the number of subjects responding 'yes' to one or more questions in each of the six of quality life indices.
Eur J Vase Endovasc Surg Vol 12, August 1996 now is that, based on the results of the earlier trial, some vascular specialists might be tempted to abandon PTA in favour of intensive walking therapy. The results from our trial cannot refute this since patients were not offered intensive walking therapy. However, we would suggest that it is justified to offer patients PTA in the expectation that their walking should be better in the short term than if they receive the most widely accepted form of non-interventional treatment, that is advice on smoking and walking and often low dose aspirin.
The improvement in walking after PTA should be reflected in an improved quality of life. The results presented here show that after 6 months more of the PTA group reported lower pain scores. The Nottingham Health Profile has been well validated and used in patients with more severe peripheral vascular disease, 19 after coronary artery bypass, 22 stroke z3 and with osteoarthritis. 24 However, one of the disadvantages of the scoring, particularly with "milder" disease such as intermittent claudication, is that a very high proportion of the answers is returned as "no", so that patients' quality of life has to be markedly impaired before a difference between treatment groups can be established. This makes the differences found in this study all the more important, but a more sensitive questionnaire might well have detected other differences. Many would argue that the use of the Nottingham Health Profile has now been superseded by quality of life scores such as the Short Form Outcomes Questionnaire (SF-36). 25 Interestingl)4 the latter has recently been used to compare (in a non-randomised study) the differences between claudicants undergoing angioplasty and those being treated conservatively, with the former showing greater improvement in some quality of life modalities. 26 There are few objective endpoints which can be used to demonstrate the superiority of any form of treatment of claudication. Treadmill exercise testing can be considered a somewhat subjective index of disease severity, but it is widely used in clinical research and in this study it has provided supportive evidence of the patient's assessment of his or her walking ability. Some have found walking distance to be poorly reproducible, 27 whilst others have shown a good correlation between claudication distance and ankle pressure. 2s It therefore seems reasonable to use the test within the confines of a randomised study. Patient reported maximum walking distance is subject to considerable bias including a placebo effect in a trial such as this. However, it could be argued that it does not matter to what extent patients benefit from a placebo effect providing they feel better, and this trial has demonstrated that they do feel better 6 months after angioplasty.
The differences between PTA and control groups at 6 months were not only statistically but also clinically significant. Despite a substantial improvement in walking in both groups over 6 months the median reported walking distance in the PTA group (lkm) was more than double that in the control group (< 1/2km) and the median treadmill distance until onset of claudication was four times greater in the PTA group (667m) than in the control group (172m). This magnitude of difference can be very important in terms of pain free achievement of the activities of daily living.
The trial has also shown that, in the short term, the deterioration of occlusive arterial disease in the legs is reduced after PTA. There were more occlusions in the control group and the stenoses were more severe. This is potentially an important finding but it is too early to know if this ultimately influences limb survival. Furthermore, occluded vessels may have a protective effect on the development of atheroma in the distal circulation 29 and PTA, in contrast to reducing disease progression, could enhance it. In considering the optimum treatment for claudication, a reduction in the need for amputation and reconstructive surgery is of paramount importance. However, such a trial would require several thousand patients and was beyond the scope of this study. Clearly, more detailed studies are required to explore this area.
In addition to the relative benefits in terms of symptomatic relief, there are other factors which need to be considered. These include the immediate risk of PTA, its consumption of resources, patient discomfort and inconvenience, the late impact on progression of disease with any method of intervention, and perhaps the ability to modify other cardiovascular risk factors such as body weight by improved exercise. Clearly, these hypotheses have not been tested in this trial. Nevertheless, there is a strong suggestion that exercise can favourably alter risk factors for atherosclerosis such as blood rheolog34 lipid profile, body weight, and hypertension and diabetic control. 3°'31 It would not, therefore, be unreasonable to postulate that improved walking after PTA has the potential to modify cardiovascular risk factors. There is also the question of whether, by not treating a simple lesion by angioplasty, a "window of opportunity" is missed after which treatment becomes more difficult and less successful. However, it is interesting that after a period of 6 months none of the patients in either group had lesions which had progressed to a point where they could not be treated by angioplasty.
Intermittent claudication accounts for a very large proportion of a vascular surgeon's out-patient workload, and PTA is a treatment option which has been available for about 20 years. 32 Despite this, very few controlled clinical trials have compared it with other treatments. 16'33 To our knowledge, this is the first report of a controlled trial showing an improvement in walking and quality of life after PTA. We conclude that in patients with claudication due to single discrete femoral artery lesions PTA offers a better outcome in the short term than best medical treatment alone. However, this is a preliminary report and further long term follow up is required to determine the extent to which these benefits are maintained. Also, larger studies are required to determine any effects on limb salvage and need for surgery.
